SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.

Pfizer Inc.

Pfizer Inc

Pfizers recent climb to a fresh yearly high and move back above a key round-number level is driving attention, with traders celebrating the breakout and bullish momentum. Others question whether the advance can hold, citing resistance, patent-cliff concerns and the lack of a clear new catalyst ahead of the quarterly report.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Attention centers on expectations for Lillys upcoming quarterly report, with traders looking for continued Mounjaro and Zepbound growth and stronger guidance after a recent run to record highs. Bulls see momentum continuing, while skeptics argue expectations are elevated and debate whether oral GLP-1 competition from Novo and Foundayo could challenge Lillys lead.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

Attention centers on ABCL635, AbCelleras investigational treatment for menopausal hot flashes: traders are weighing its positive Phase 2 results and additional clinical data presented at a menopause conference. The reaction is broadly bullish, reinforced by new analyst coverage, but some say the news may already be priced in and emphasize that further trials are needed to confirm the findings.

Papa John's International, Inc. engages in the operation and franchise of pizza delivery and carryout restaurants. It operates through the following segments: Domestic Company-owned Restaurants, North America Franchising, North America Commissaries, International Operations, and All Others. The Domestic Company-Owned Restaurants segment consists of retail sales of pizza and side items, breadsticks, cheese sticks, chicken poppers and wings, dessert items, and canned and bottled beverages. The North America Franchising segment involves the offering of sales and support activities, development rights, and collection of royalties from franchisees located in the United States and Canada. The North America Commissaries segment includes the eleven full-service regional dough production and distribution and quality control centers. The International Operations segment represents all restaurant operations outside of the United States and Canada. The All Others segment focuses on franchise contributions to marketing funds and sale, company-owned and franchised restaurants, information systems and related services used in restaurant operations, point-of-sale system, online and other technology-based ordering platforms, printing, and promotional items. The company was founded by John H. Schnatter in 1984 and is headquartered in Louisville, KY.

Papa John`s International, Inc.

A reported take-private bid involving Papa Johns largest U.S. franchisee has fueled renewed buyout speculation and a sharp rally. Traders are debating whether the board will accept or negotiate, while skeptics point to weak sales and the suspended dividend; no deal is confirmed.

Atlassian Corp. is a holding company, which engages in providing team collaboration and productivity software. Its products include Jira Software, Confluence, Jira Service Management, and Loom. The company was founded by Michael Cannon-Brookes and Scott Farquhar in October 2002 and is headquartered in San Francisco, CA.

Atlassian Corporation - Ordinary Shares - Class A

Atlassian Corporation Plc

A sharp rebound and breakout in Atlassian shares, supported by strong cloud growth and repeated analyst upgrades, has fueled bullish momentum and renewed optimism about software stocks ability to benefit from AI. Traders are divided over whether the move can continue or is overextended ahead of earnings, with some warning of a pullback and persistent concerns about valuation and AI disruption.

ExxonMobil Holdings Corp. is an international energy and petrochemical company, which creates solutions that improve quality of life and meets society’s evolving needs. The company is headquartered in Spring, TX.

ExxonMobil Holdings Corp.

Exxon Mobil Corp

Exxon is drawing attention as crude prices rise amid Middle East supply concerns and traders anticipate a strong refining contribution to its upcoming quarterly report. The community is debating whether refining strength can offset weaker upstream results and how long the margin boost will last.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsofts upcoming quarterly report is the dominant focus, with traders watching Azure growth and whether AI demand can justify rising data-center spending. Views are split between confidence in cloud and AI momentum and concern that heavy capex, delayed returns, and depreciation could pressure margins.

Petróleo Brasileiro SA engages in oil and gas exploration, production, and distribution activities. It operates through the following segments: Exploration and Production; Refining, Transportation, and Marketing; and Gas and Low Carbon Energies. The Exploration and Production segment covers the activities of exploration, development, and production of crude oil, natural gas liquid, and natural gas, for the primary purpose of supplying its domestic refineries. The Refining, Transportation, and Marketing segment refers to refining, logistics, transport, and trading of crude oil and oil products activities as well as exports of ethanol. The Gas and Low Carbon Energies represents the activities of logistic and trading of natural gas and electricity, transportation and trading of liquefied natural gas, generation and electricity by means of thermoelectric power plants, as well as holding interests in transporters and distributors of natural gas. The company was founded on October 3, 1953 and is headquartered in Rio de Janeiro, Brazil.

Petroleo Brasileiro S.A. Petrobras - ADR

Petroleo Brasileiro

Traders are focused on Brazils presidential runoff and the possibility of Flvio Bolsonaro winning, with speculation that a change in government could bring more shareholder-friendly policies and lift Petrobras shares. Bullish election positioning is tempered by uncertainty about the result and the risk of a sell-the-news reaction; higher oil prices are also supporting the discussion.

FMC Corp. is an agricultural sciences company, which engages in the provision of solutions to growers and development of pipeline in crop protection, plant health, agriculture, pest control, and turf management. It offers insect control products under the Rynaxypyr and Cyazypyr brands. The company was founded by John Bean in 1883 and is headquartered in Philadelphia, PA.

FMC Corp.

FMCs sharply reduced third-quarter outlook, driven by weak demand and price adjustments to clear excess distributor inventory, has intensified concern about its earnings, debt burden and potential bankruptcy risk. Bulls argue the reset is a one-time step toward recovery and point to debt-reduction efforts, while skeptics doubt the turnaround and warn of further financial distress.

Chevron Corp. engages in the provision of oil and gas energy solutions. It provides crude oil and natural gas, manufactures transportation fuels, lubricants, petrochemicals, and additives, and develops technologies that enhance business and the industry. It operates through the Upstream and Downstream segments. The Upstream segment consists of the exploration, development, and production of crude oil and natural gas, the liquefaction, transportation, and regasification associated with liquefied natural gas, the transporting of crude oil by major international oil export pipelines, the processing, transporting, storage, and marketing of natural gas, and a gas-to-liquids plant. The Downstream segment consists of the refining of crude oil into petroleum products, the marketing of crude oil and refined products, the transporting of crude oil and refined products by pipeline, marine vessel, motor equipment, and rail car, and the manufacturing and marketing of commodity petrochemicals and plastics for industrial uses and fuel & lubricant additives. The company was founded on September 10, 1879 and is headquartered in Houston, TX.

Chevron Corp.

Chevrons breakout to record highs is drawing attention, with traders pointing to firm crude prices and supply-risk concerns while positioning ahead of its earnings report. Sentiment is mostly bullish, though some question whether strong energy markets will last and whether the rally has already priced in the results.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

INSM Stock Slides on CFO Exit, Reiterates '26 Sales View

Insmed shares slide after CFO Sara Bonstein's surprise exit, though the company reaffirms 2026 revenue guidance for Brinsupri and Arikayce.

AGIO Stock Sinks 29% in Three Months: Here's What You Need to Know

Agios faces a narrower growth path as tebapivat setbacks shift focus to mitapivat sales, SCD expansion and regulatory prospects.

PCRX Expands Exparel Commercial Reach in Europe Through Molteni Deal

Pacira expands Exparel's European reach through Molteni, adding new markets and revenue streams, with the first commercial sale in Europe expected in 2027.

Novartis Strengthens RNA Therapeutics Pipeline With $7.8B Abogen Deal

NVS gains global rights to Abogen's ABO2203, expanding its RNA therapeutics push with a potential new approach to B-cell-mediated autoimmune diseases.

Ultragenyx's Gene Therapy for Sanfilippo Syndrome Wins EMA Validation

RARE's gene therapy for Sanfilippo syndrome wins EMA validation, advancing the treatment toward formal review in Europe.

Novo's Denecimig BLA Review Delayed by FDA Facility Remediation Work

NVO's denecimig FDA review is delayed by manufacturing facility remediation, while no clinical efficacy or safety deficiencies were identified.

UTHR Prevails in LQDA's Yutrepia Patent Dispute, Stock Up Nearly 13%

United Therapeutics secures a key patent ruling against Liquidia, potentially limiting Yutrepia's PH-ILD use and reducing competition for its Tyvaso products.

Novo's Wegovy Pill Shows Weight Loss After Switching From Injections

NVO's Wegovy pill delivers an average weight loss of 4.1% after three months for adults switching from injectable GLP-1 therapies.

Merck's Tulisokibart Meets Endpoints in Hidradenitis Suppurativa Study

MRK's tulisokibart meets the phase IIb HS study's primary endpoint, with high and medium-dose regimens showing superiority over placebo at week 16.

NVO's Ozempic Outshines LLY's Mounjaro in Lowering Cardiovascular Risk

Novo's real-world study finds that patients who increase their Ozempic to 2 mg have a lower observed MACE risk than those who switch to Mounjaro.

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eliseev on February 13, 2003 and is headquartered in Lausanne, Switzerland.

AC Immune SA

ACIU Stock Heads For Best Day In Over 10 Months On FDA Fast Track Nod For Parkinson’s Disease Therapy – Retail Sees ‘Breakout Soon’

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>The FDA also cleared the company’s Investigational New Drug application.</li><li>The full 100-week results from the first part of the trial are expected in the second half of 2026.</li><li>AC Immune has total cash resources of $92.9 million, which it expects to fund operations into the fourth quarter of 2027.</li></ul>Shares of AC Immune (ACIU) surged more than 16% on Tuesday, after the U.S. Food and Drug Administration granted Fast Track designation to its experimental immunotherapy for early-stage Parkinson’s disease.<a href="https://stocktwits.com/symbol/ACIU">ACIU shares</a> are on track to clock their biggest intraday gains since October 2025.<h2 class="st-heading-2">FDA Clears Investigational New Drug Application</h2>Fast Track designation is intended for treatments targeting serious diseases with unmet medical needs. It allows AC Immune to communicate with the FDA more frequently during the trials. AC Immune’s ACI-7104 could also become eligible for accelerated approval or priority review if it meets the relevant requirements.However, the designation does not mean that the treatment has been approved or that its effectiveness has been established.The FDA also cleared the company’s Investigational New Drug (IND) application, allowing the ongoing Phase 2 VacSYn study to expand to clinical sites in the U.S.<h2 class="st-heading-2">Full Results Expected In Second Half Of 2026</h2>ACI-7104 is designed to generate antibodies that target toxic, aggregated forms of a protein called alpha-synuclein. The buildup of this protein is linked to inflammation and the loss of brain cells associated with Parkinson’s disease.Interim results from the trial showed that the therapy was generally safe and well tolerated through 76 weeks, with no clinically significant safety concerns. All treated patients produced the targeted immune response, giving the study a 100% responder rate.The full 100-week results from the first part of the trial are expected in the second half of 2026. According to AC Immune’s quarterly statements last week, the firm has total cash resources of CHF75.4 million ($92.9 million), which it expects to fund operations into the fourth quarter of 2027.<h2 class="st-heading-2">ACIU Bulls Eye Breakout</h2>Retail sentiment surrounding ACIU on Stocktwits turned ‘bullish’ from ‘neutral’ over the past 24 hours, amid ‘high’ message volumes.One user said the fast-track designation could lead to the stock breaking out “soon.”<stembedurl>https://stocktwits.com/BLD33/message/661530497</stembedurl>ACIU shares have declined more than 25% so far in 2026.(Exchange Rate: CHF1 = $1.23)Also read: <a href="https://stocktwits.com/news-articles/markets/equity/citi-says-hims-and-hers-full-year-outlook-indicates-hefty-q4-earnings-lift-warns-of-execution-risks/cZoNbc5RJQC">Citi Says Hims &amp; Hers’ Full-Year Outlook Indicates ‘Hefty’ Q4 Earnings Lift, Warns Of Execution Risks</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CHINA - 2025/10/02: In this photo illustration, the AC Immune logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

The U.S. Food and Drug Administration granted Fast Track designation to AC Immune’s experimental immunotherapy ACI-7104 for early-stage Parkinson’s disease.

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Stocktwits

Stocktwits Polls

$ACIU Dr. Tamara Seredenina from AC Immune will give an oral presentation titled "First-in-Human Evaluation of [¹⁸F]ACI-19626, a Novel TDP-43 PET Tracer (#4006)". The presentation is taking place in Salon H during Plenary Session 6 (HOT Topics) at the International Symposium on Frontotemporal Dementias (ISFTD 2026 
AC Immune is scheduled to present on Sunday, October 11, 2026, from 8:30 AM to 8:45 AM 
, Dr. Tamara Seredenina is expected to present new clinical data from the ongoing clinical trial of [¹⁸F]ACI-19626. 
First-in-Human Clinical Evaluation: The presentation will detail updated results from the Phase 1 first-in-human trial (NCT06891716) evaluating how safely and reliably this novel PET tracer detects abnormal TDP-43 protein accumulation in the brain.

midas7576

$ACIU Im really confident, that we see a 4,xx till the end of the year. The marketcap is way to low regarding all those strong partnerships and possible Milestonepayments. I unterstand, that cash runaway is a thread, but they still have a strong pipline fully owned. 270 million marketcap is a joke.

Marko Schuster

$ACIU 

Holding for Parkinson’s and Alzheimer’s breakthrough. 

5-10 years horizon with 10000% potential. 

JMO

Feed

News

Sentiment

Earnings

Fundamentals

Info

ACIU AC Immune SA

Fundamentals

Latest ACIU News